BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN BEGIN:VTIMEZONE TZID:Mountain Standard Time BEGIN:STANDARD DTSTART:20231102T020000 RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11 TZNAME:Mountain Standard Time TZOFFSETFROM:-0600 TZOFFSETTO:-0700 END:STANDARD BEGIN:DAYLIGHT DTSTART:20230301T020000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3 TZNAME:Mountain Daylight Time TZOFFSETFROM:-0700 TZOFFSETTO:-0600 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:This presentation by Enkhtsetseg Purev\, MD\, PhD\, will discus s approaches to harness T-cell activity for the treatment of patients with NHL\, with focus on the anti-CD20/CD3 bispecific antibodies mosunetuzumab and glofitamab\n \;\nPLEASE NOTE THAT CE CREDIT WILL NOT BE OFFERED F OR THIS SESSION.\n \;\nClick here to register for this presentation DTEND:20211104T190000Z DTSTAMP:20240329T002229Z DTSTART:20211104T180000Z LOCATION: SEQUENCE:0 SUMMARY:Hematology Symposia Series - Biospecific Antibodies - with Enkhtse tseg Purev\, MD\, PhD UID:RFCALITEM638472469495524119 X-ALT-DESC;FMTTYPE=text/html:
This presentation by Enkhtsetseg Purev\, MD \, PhD\, will discuss approaches to harness T-cell activity for the treatm ent of patients with NHL\, with focus on the anti-CD20/CD3 bispecific anti bodies mosunetuzumab and glofitamab
\n \;
\nPLEASE NOTE TH AT CE CREDIT WILL NOT BE OFFERED FOR THIS SESSION.
\n \;
\n END:VEVENT END:VCALENDAR